NEW YORK: Pfizer executives said Tuesday they are confident of strong demand for the company's COVID-19 antiviral treatment amid easing pandemic rules as the big drugmaker reported another round of strong earnings.
Citing rising vaccine fatigue, Bourla said the company is also focused on a Covid-19 vaccine booster that provides immunity for a year. Pfizer lowered its full-year adjusted profits by 10 cents to US$6.25 to US$6.45 a share, due in part to currency movements. In the first quarter, Paxlovid took in US$1.5 billion in global sales. But Pfizer expects 2022 sales of the medicine of US$22 billion as it ramps up production and distribution.
"What we are seeing is ... there is demand for this product," said Pfizer biopharmaceuticals group president Angela Hwang, citing the removal of mask mandates as a factor in spreading cases.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: thenewpaper - 🏆 7. / 63 Read more »